Healthcare stocks are poised for a significant move on Monday following reports that AbbVie (ABBV) is nearing a $10.9 billion cash acquisition of Apogee Therapeutics (APOG). The deal, which could be announced as early as Monday, represents a roughly 60% premium over Apogee's closing price on Thursday. Neither company has confirmed the talks, leaving room for potential changes or collapse.
The report emerged on Friday while U.S. markets were closed for Juneteenth, preventing any immediate trading reaction. Markets remain shut over the weekend and will reopen at 9:30 a.m. EDT on June 22. AbbVie and Apogee are expected to be among the most active names when trading resumes, with the broader healthcare sector also drawing attention.
Apogee's lead drug candidate, zumilokibart, is an IL-13 blocker targeting inflammation and competes directly with Regeneron (REGN) and Sanofi's (SNY) blockbuster Dupixent. The company plans to initiate Phase 3 trials in the second half of 2026 to evaluate safety and efficacy. For AbbVie, the acquisition would bolster its pipeline amid declining Humira sales, which fell 38.6% in the first quarter.
The healthcare sector has struggled recently, with the Health Care Select Sector SPDR Fund (XLV) declining nearly 3% over the four sessions through June 18. In contrast, the S&P 500 gained 0.93% during the same period. XLV's heavy weighting in Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie means that large moves in these names significantly impact the ETF's performance.
Biotechnology stocks showed mixed results last week. UniQure's (QURE) U.S. shares surged over 75% after the FDA indicated that current data might support an accelerated-approval application for its Huntington's disease drug. Accelerated approval allows earlier market entry based on preliminary data but typically requires confirmatory studies. Guggenheim analyst Debjit Chattopadhyay noted the decision could signal the FDA's willingness to consider the challenges of rare diseases. William Blair's Myles Minter added that the regulator "appears to be more flexible on regulatory paths."
Moderna (MRNA) shares rose 3.5% on Thursday after an FDA advisory panel voted to recommend its mFlusiva flu vaccine for adults over 50. The FDA is expected to make a final decision by August 5. However, Citi's Geoff Meacham cautioned that significant revenue from the vaccine is unlikely before the second half of 2027, citing Moderna's miss of the current U.S. contracting cycle.
Clinical setbacks were also notable. Neumora Therapeutics (NMRA) plunged 50% after discontinuing a depression candidate following multiple late-stage trial failures and announcing a 35% workforce reduction. RBC analyst Brian Abrahams suggested the steep decline could represent "a particularly interesting entry point for a revamped go-forward story." Edgewise Therapeutics (EWTX) dropped nearly 10% after its heart drug data disappointed investors, though RBC's Leonid Timashev described the drug's efficacy as "clearly competitive" and its safety as "unmatched in the space."
Beyond the AbbVie-Apogee deal, investors will focus on Thursday's economic data, including the third reading of Q1 GDP and May personal income and spending figures at 8:30 a.m. EDT. The core PCE inflation measure, which excludes food and energy, will be released within the income and spending report. A hot inflation reading could push bond yields higher, pressuring biotech stocks that rely on future earnings for valuation.
Risks remain significant. The AbbVie-Apogee talks could stall, change terms, or fall apart entirely. Zumilokibart has not yet entered Phase 3 trials, and Apogee has noted in its filings that side effects, trial delays, or requests for additional data could hinder the drug's progress or reduce future sales. While the FDA showed flexibility on one rare-disease project, this does not guarantee similar treatment for the broader sector.
Large pharmaceutical and insurance names continue to trade softly, capping the benchmark's upside. For now, any recovery in healthcare depends on these heavyweights finding support, even as small biotech stocks see spikes and acquisition interest grows. Traders are watching whether buyout rumors and a slightly more accommodating FDA can spark a turnaround, but the sector remains near its lows until the largest components attract buying interest.
